Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
LA PALMA, Calif. - Liminatus Pharma, Inc. (NASDAQ:LIMN), a $165 million market cap company whose stock has declined over 50% in the past six months, has initiated a strategic review to evaluate the potential inclusion of regulated digital assets in its treasury management framework, according to a press release statement issued Tuesday. InvestingPro analysis indicates the stock has shown high price volatility in recent months.
The preclinical-stage biopharmaceutical company, which focuses on developing targeted cancer immunotherapies, emphasized that the review is exploratory and does not represent a shift from its core business focus. According to InvestingPro data, the company currently maintains a weak financial health score, with negative earnings of $0.14 per share in the last twelve months.
"Liminatus remains fully committed to our mission of developing life-changing cancer therapies," said Chris Kim, CEO of Liminatus Pharma. "This review is not a shift in our business focus, but an effort to evaluate modern financial tools that may enhance the way we manage non-operating capital."
The company has not entered into any agreements regarding the acquisition, custody, or use of digital assets. Any potential future steps would require approval from the Board of Directors and would be conducted in accordance with SEC regulations and public company disclosure standards.
Liminatus stated that the internal review aligns with its commitment to financial stewardship and balance sheet optimization while maintaining its primary focus on advancing cancer therapies.
The company is currently in the preclinical stage of developing immunotherapies targeting cancer antigens and tumor-specific immune responses. Based on InvestingPro’s Fair Value analysis, the stock appears overvalued at current levels. Subscribers can access 4 additional ProTips and comprehensive financial metrics to better understand the company’s potential.
In other recent news, Liminatus Pharma has made several notable announcements. The company has entered into a settlement agreement with Alta Partners, exchanging 1 million warrants for 350,000 shares of common stock. This transaction was completed without any commission or remuneration and was exempt from registration under the Securities Act of 1933. Additionally, Liminatus Pharma has expanded its board of directors by appointing Philip Lemons and Richard Baek, bringing the total number of directors to six. The company has also formed a consortium with Samda Biolab and INNOCS AI to develop a blood-based diagnostic kit for early detection of pancreatic cancer, which demonstrated high sensitivity and specificity in recent clinical data. Furthermore, Liminatus Pharma announced it has regained compliance with Nasdaq’s listing requirements after addressing a previous delay in filing its Quarterly Report. These developments reflect the company’s ongoing efforts in strategic partnerships and corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.